More PRNewswire
View Older Stories View Newer Stories-
The Third Liangzhu Forum Opens in Hangzhou, Zhejiang
-
Liquid Wind and Umeå Energi Finalise Agreements to Commercialise eFuel Facility in Umeå, Sweden
-
Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power
-
Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions
-
China International College Students' Innovation Competition 2025 Finals Conclude in Zhengzhou
-
MILESEEY GenePro G1 Named to TIME's "The Best Inventions of 2025: Special Mentions"
-
Chengdu CATANIA's Tower 2 Debuts Globally: A 222-Meter-High Sky Residence Redefining Global Luxury Living.
-
Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO
-
Paratus Announces Receipt of Payment in Mexico
-
Comfone Launches 5G SA Roaming with BroadForward SEPP
-
Zeekr Group to Report Third Quarter 2025 Financial Results on November 17, 2025
-
A Scoop for Amsterdam: ARTIS Zoo officially recognized for protection of nocturnal darkness
-
Global Times 'Overseas China Week' photo exhibition in Seoul highlights China-South Korea friendship and exchanges
-
Press Conference for 2025 World Internet Conference Wuzhen Summit Held in Beijing
-
HTX Launches the "Sail Together" Initiative, Airdropping 100 Million USDT to Help Global Traders Weather Market Turbulence
-
Quantitative Brokers Expands into Latin America with Launch of Execution Algorithms on Brazil's B3 Exchange
-
Kyndryl Readiness Report: AI Delivers Early Returns, Pushing Enterprises to a Tipping Point
-
BC.GAME Esports Signs CS Major Champion electronic
-
Chery Group Renews US$6 Million Partnership with UNICEF to Advance Global Education
-
Grand Opening of the 2025 Sustainable Global Leaders Conference: Kevin Kelly and the Turing Award Winner Share AI Frontiers, Business Leaders Discuss Sustainable Development
-
Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
-
Redefines the Future of TV: SKYWORTH Unveils All-New Matte Screen Ultra TV Series at the 138th Canton Fair
-
Xinhua Silk Road: Financial Street Forum annual conference to be held on Oct. 27-30 in Beijing
-
Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
-
CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025
-
ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
-
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
-
Prime Minister Celebrates Opening of Cambodia's State-of-the-art International Airport
-
IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety
-
Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances
-
Leading Competition Economist Dr. Luke Wainscoat Joins The Brattle Group
-
CLARINS & V MAGAZINE CELEBRATE HIGH-PERFORMANCE BEAUTY WITH A STAR-STUDDED GOLDEN HOUR EVENT IN AUSTIN
-
Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report
-
Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025
-
HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet
-
iOncologi Secures Foundational U.S. Patent as Landmark Studies Link COVID19 mRNA Vaccines to Improved Survival with Cancer Immunotherapy
-
Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
-
VT3989, Vivace Therapeutics' Best-in-Class, Hippo Pathway-Targeting Therapy, Demonstrates Promising Antitumor Activity in Refractory Mesothelioma
-
Global Times: Over 400 senior guests from over 30 countries, regions to attend conference of Financial Street Forum 2025 in Beijing: organizers
-
/C O R R E C T I O N -- Spinogenix/
-
United Imaging Marks Five Years Since the Opening of its Global Showroom In North America with a Record Number of U.S. Customer Visits
-
Max Stock Limited releases an immediate report on holdings of interested parties and senior officers as of September 30, 2025
-
HDAI to announce AI tools that drive quality outcomes at HLTH 2025
-
PayrollOrg's Educational Institutions Payroll Conference to Equip Higher Ed Payroll Professionals with Essential Compliance and Technology Insights
-
SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented as a Late-Breaking Oral Presentation at E
-
Startuprad.io Launches Startup AI Concierge for Europe's Startup Ecosystem
-
World Winter Sports Expo 2025 Officially Opened
-
Falcon Finance Publishes Strategy Allocation Breakdown for Yield Generation Transparency
-
The 2025 Chery International User Summit Opens a New Chapter as AiMOGA Robotics Unveils Its Global Brand Strategy
-
Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced
